{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Philadelphia&page=53&state=Pennsylvania",
    "query": {
      "state": "Pennsylvania",
      "city": "Philadelphia",
      "page": 53
    },
    "page_size": 10
  },
  "pagination": {
    "page": 53,
    "page_size": 10,
    "total_count": 17147,
    "total_pages": 1715,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Philadelphia&page=54&state=Pennsylvania&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Philadelphia&page=52&state=Pennsylvania&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T14:57:59.740Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03086369",
      "title": "A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Olaratumab",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2017-06-22",
      "completion_date": "2021-06-17",
      "has_results": true,
      "last_update_posted_date": "2022-06-28",
      "last_synced_at": "2026-11-19T14:57:59.740Z",
      "location_count": 32,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 26 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03086369"
    },
    {
      "nct_id": "NCT04506554",
      "title": "A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "AMVAC + Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2020-12-01",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-19T14:57:59.740Z",
      "location_count": 4,
      "location_summary": "Chapel Hill, North Carolina • Philadelphia, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04506554"
    },
    {
      "nct_id": "NCT03400254",
      "title": "Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACIER\")",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine (HCQ)",
          "type": "DRUG"
        },
        {
          "name": "Gedatolisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-02-26",
      "completion_date": "2019-11-12",
      "has_results": false,
      "last_update_posted_date": "2020-04-28",
      "last_synced_at": "2026-11-19T14:57:59.740Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03400254"
    },
    {
      "nct_id": "NCT01602666",
      "title": "Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System Nongerminomatous Germ Cell Tumor",
        "Childhood Germinoma"
      ],
      "interventions": [
        {
          "name": "3-Dimensional Conformal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 262,
      "start_date": "2012-06-27",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-11-19T14:57:59.740Z",
      "location_count": 149,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Downey, California + 115 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01602666"
    },
    {
      "nct_id": "NCT03217266",
      "title": "Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Resectable Soft Tissue Sarcoma",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Navtemadlin",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2018-06-20",
      "completion_date": "2025-09-04",
      "has_results": true,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-11-19T14:57:59.740Z",
      "location_count": 53,
      "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03217266"
    },
    {
      "nct_id": "NCT00014651",
      "title": "Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Perioperative/Postoperative Complications"
      ],
      "interventions": [
        {
          "name": "vapreotide",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": null,
      "start_date": "2001-03",
      "completion_date": "2002-04",
      "has_results": false,
      "last_update_posted_date": "2010-08-10",
      "last_synced_at": "2026-11-19T14:57:59.740Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014651"
    },
    {
      "nct_id": "NCT06973629",
      "title": "Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis (ALS)",
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "Debamestrocel - MSC-NTF (NurOwn)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Brainstorm-Cell Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-06-30",
      "completion_date": "2029-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-11-19T14:57:59.740Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06973629"
    },
    {
      "nct_id": "NCT06954129",
      "title": "A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Cefepime",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 750,
      "start_date": "2026-01-28",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-11-19T14:57:59.740Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06954129"
    },
    {
      "nct_id": "NCT02117479",
      "title": "Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 321,
      "start_date": "2014-03",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2019-03-26",
      "last_synced_at": "2026-11-19T14:57:59.740Z",
      "location_count": 153,
      "location_summary": "Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 150 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02117479"
    },
    {
      "nct_id": "NCT03428646",
      "title": "Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 858,
      "start_date": "2018-04-06",
      "completion_date": "2027-07-28",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-19T14:57:59.740Z",
      "location_count": 93,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 83 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03428646"
    }
  ]
}